Carfilzomib Usage Patterns and Outcomes in Patients with Relapsed Multiple Myeloma: A Multi-institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Overview

Journal EJHaem

Specialty Hematology

Date 2022 Dec 5

PMID 36467802

Authors

Arleigh McCurdy

Martha Louzada

Christopher P Venner

Alissa Visram

Esther Masih-Khan

Moustafa Kardjadj

Victor H Jimenez-Zepeda

Richard LeBlanc

Michael Sebag

Kevin Song

Darrell White

Hira Mian

Julie Stakiw

Anthony Reiman

Muhammad Aslam

Rami Kotb

Engin Gul

Donna Reece

Affiliations

Soon will be listed here.

Abstract

Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relapse of MM in a real-world setting in Canada between years 2007 and 2020. A total of 445 patients were included in this study: the doublet (Kd/p, = 218) and triplets (KCd, = 88; KRd, = 99; KPd/p, = 40). One hundred and twenty-two (27%) received carfilzomib-based treatment in line 2, 133 (30%) in line 3, 90 (20%) in line 4, and 100 (23%) in line 5 or higher. Carfilzomib was dosed weekly in 40% of patients and twice weekly in 60%. The overall response rate of the entire cohort was 57.7%, with 33.6% of patients achieving very good partial response or better. Median progression-free survival for the overall cohort was 6.3 months with overall survival 19.7 months. This study provides a benchmark for carfilzomib-based regimens in the real world, demonstrating that these regimens are effective in treating patients with relapsed MM.

Citing Articles

Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study.

Hulin C, Quignot N, Jiang H, Mechiche H, Desamericq G EJHaem. 2024; 5(4):887-891.

PMID: 39157605 PMC: 11327767. DOI: 10.1002/jha2.946.

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.

McCurdy A, Louzada M, Venner C, Visram A, Masih-Khan E, Kardjadj M EJHaem. 2022; 3(4):1252-1261.

PMID: 36467802 PMC: 9713064. DOI: 10.1002/jha2.559.

References

Moreau P, Mateos M, Berenson J, Weisel K, Lazzaro A, Song K . Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018; 19(7):953-964. DOI: 10.1016/S1470-2045(18)30354-1. View

Venner C, LeBlanc R, Sandhu I, White D, Belch A, Reece D . Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial. Am J Hematol. 2021; 96(5):552-560. DOI: 10.1002/ajh.26147. View

Pennipede D, Mohyuddin G, Hawkins R, Ganguly S, Shune L, Ahmed N . Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM). Eur J Haematol. 2021; 107(6):602-608. DOI: 10.1111/ejh.13697. View

Mian H, Wildes T . Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. Drugs Aging. 2018; 35(4):289-302. DOI: 10.1007/s40266-018-0539-1. View

Mian H, Fiala M, Sanchez L, Vij R, Wildes T . Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world". Ann Hematol. 2021; 100(5):1261-1266. PMC: 8054467. DOI: 10.1007/s00277-021-04420-3. View

Obeng E, Carlson L, Gutman D, Harrington Jr W, Lee K, Boise L . Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006; 107(12):4907-16. PMC: 1895817. DOI: 10.1182/blood-2005-08-3531. View

Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A . Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019; 20(1):8-17.e16. DOI: 10.1016/j.clml.2019.09.625. View

Stewart A, Rajkumar S, Dimopoulos M, Masszi T, Spicka I, Oriol A . Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2014; 372(2):142-52. DOI: 10.1056/NEJMoa1411321. View

Usmani S, Quach H, Mateos M, Landgren O, Leleu X, Siegel D . Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2021; 23(1):65-76. DOI: 10.1016/S1470-2045(21)00579-9. View

10.

Yang G, Gao M, Zhang Y, Kong Y, Gao L, Tao Y . Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget. 2015; 6(29):26982-94. PMC: 4694968. DOI: 10.18632/oncotarget.4831. View

11.

Palumbo A, Chanan-Khan A, Weisel K, Nooka A, Masszi T, Beksac M . Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 375(8):754-66. DOI: 10.1056/NEJMoa1606038. View

12.

Landgren O, Sonneveld P, Jakubowiak A, Mohty M, Iskander K, Mezzi K . Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019; 33(9):2127-2143. PMC: 6756042. DOI: 10.1038/s41375-019-0517-6. View

13.

Siegel D, Dimopoulos M, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A . Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018; 36(8):728-734. DOI: 10.1200/JCO.2017.76.5032. View

14.

Fakhri B, Fiala M, Shah N, Vij R, Wildes T . Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. Cancer. 2019; 126(4):808-813. PMC: 6992490. DOI: 10.1002/cncr.32601. View

15.

Dimopoulos M, Goldschmidt H, Niesvizky R, Joshua D, Chng W, Oriol A . Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017; 18(10):1327-1337. DOI: 10.1016/S1470-2045(17)30578-8. View

16.

Lee J, Park Y, Kang K, Lee J, Lee H, Eom H . Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. Ann Hematol. 2021; 100(8):2051-2059. DOI: 10.1007/s00277-021-04407-0. View

17.

McCurdy A, Louzada M, Venner C, Visram A, Masih-Khan E, Kardjadj M . Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. EJHaem. 2022; 3(4):1252-1261. PMC: 9713064. DOI: 10.1002/jha2.559. View

18.

Kuhn D, Chen Q, Voorhees P, Strader J, Shenk K, Sun C . Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007; 110(9):3281-90. PMC: 2200918. DOI: 10.1182/blood-2007-01-065888. View

19.

McCurdy A, Venner C, Masih-Khan E, Louzada M, LeBlanc R, Sebag M . Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. Curr Oncol. 2022; 29(3):1575-1582. PMC: 8946875. DOI: 10.3390/curroncol29030132. View

20.

Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T . NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002; 277(19):16639-47. DOI: 10.1074/jbc.M200360200. View